Submissions
Cancer Voices Australia has made the following submissions on behalf of people affected by cancer (most recent first).
- Review of Pharmacy Remuneration and Regulation 2016
- Priority issues for Australians affected by cancer
- ANAO Review of the Radiation Oncology Health Program Grants
- Orphan Drugs
- Medicare Safety Net (MSN) changes – Further concerns for cancer patients
- Consumer concerns re IP Australia’s proposal to negate High Court Decision re patents on genes; and call to amend the Patents Act to reflect the High Court’s decision
- Medical Research Future Fund Bill 2015 and Medical Research Future Fund (Consequential Amendments) Bill 2015
- Address to the Senate Legal and Constitutional Affairs Legislation Committee’s Inquiry – Regulator of Medical Cannabis Bill 2014 – 31 March 2015
- Senate Legal and Constitutional Affairs Committee Inquiry – Regulator of Medicinal Cannabis Bill 2014
- Medical Services Advisory Committee – Availability of IMRT and IGRT to Australian cancer patients
- Therapeutic Goods Administration – Orphan Drugs
- Senate Community Affairs References Committee Inquiry – The availability of new, innovative and specialist cancer drugs in Australia
- Medicines Australia Code of Conduct
- Application 1380 – Germline BRCA mutation testing to determine eligibility for olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal cancer) with high grade serous features or high grade serious component
- CVA comment on ACCC determination in respect of the Medicines Australia Code of Conduct Edition 18
- Inquiry into skin cancer
- Senate Inquiry into Out-of-pocket costs in Australian Healthcare
- Proposed amendments to the Medicines Australia Code of Conduct
- MSAC: 1357-F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer
- MSAC: Radium 223 (Xofigo) for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases (No 12687)
- Changes to premarket assessment requirements
- Submission to the Senate Inquiry re supply of chemotherapy drugs such as Docetaxel
- Supplementary submission to Senate Community Affairs References Committee hearing on Supply of chemotherapy drugs such as Docetaxel (Sydney March 2013)
- Pharmaceutical Patents Review Panel’s Background and Suggested Issues Paper (Nov 2012)
- Presentation to Coalition Backbench Policy Committee 24 June 2013
- Review of funding arrangements for chemotherapy services
- ANAO Audit: Administration of Fifth Community Pharmacy Agreement (5PCA)
Position statements
Cancer Voices Australia is developing and updating Position Statements on the following topics.
Those with links have been completed or updated.
- Informed Financial Consent Choice in Cancer Treatment (June 2018)
- Equity of access to Selective Internal Radiotherapy Treatment (SIRT)
- Informed decision making – about cancer treatment options and costs
- Cancer survivors’ framework for survivorship care
- Supporting consumers to attend cancer conferences
- Best practice consumer representation
- Access to high cost cancer drugs
- 2013 election issues for Australians affected by cancer
- Comprehensive cancer centres
- Consumer advocacy training
- Consumer engagement: Template for stakeholders
- Directories of cancer specialists
- Dying with dignity and control
- Medicare items – lymphoedema garments etc
- Palliative care access
- Patenting of human genes – legislative reform
- Patient charter
- Personalised medicine
- PET Scan and MRI: MBS Subsidies
- Pharmaceutical industry relationships
- Private health insurance – issues
- Radiotherapy access
- Research – consumer involvement
- Rural and remote issues
- Screening programs
- Stigma of cancer
- Workforce shortages: Cancer specialists